TY - JOUR
T1 - Molecular monitoring of organ recipients from cancer-affected donors by detection of circulating tumor cells
AU - Gabusi, E.
AU - Corti, B.
AU - D'Errico, A.
AU - Ridolfi, L.
AU - Ercolani, G.
AU - Venettoni, S.
AU - Costa, A. N.
AU - Grigioni, W. F.
PY - 2004/6
Y1 - 2004/6
N2 - We have initiated regular molecular monitoring based on nested RT-PCR detection of circulating tumor cells for monitoring recipients of organs from cancer-affected donors in Italy (in the context of a "Donation Safety and Donated Organ Quality" project organized by the Centro Nazionale Trapianti). Five patients are being monitored. For two patients who each received a kidney from a single donor with prostate adenocarcinoma, RT-PCR was performed using PSA mRNA. For three recipients of organs (two livers and one kidney) from donors with renal cell carcinoma, RT-PCR was performed using cytokeratine 18 and 19 mRNA. Blood samples from five healthy subjects were used as negative controls. After a median monitoring time of 26 months (range 8 to 32), none of the regular 3-month assays has tested positive. This pilot study suggests that detection of circulating tumor cells by nested RT-PCR may provide a feasible molecular monitoring, which might assist decision making regarding other forms of clinical surveillance.
AB - We have initiated regular molecular monitoring based on nested RT-PCR detection of circulating tumor cells for monitoring recipients of organs from cancer-affected donors in Italy (in the context of a "Donation Safety and Donated Organ Quality" project organized by the Centro Nazionale Trapianti). Five patients are being monitored. For two patients who each received a kidney from a single donor with prostate adenocarcinoma, RT-PCR was performed using PSA mRNA. For three recipients of organs (two livers and one kidney) from donors with renal cell carcinoma, RT-PCR was performed using cytokeratine 18 and 19 mRNA. Blood samples from five healthy subjects were used as negative controls. After a median monitoring time of 26 months (range 8 to 32), none of the regular 3-month assays has tested positive. This pilot study suggests that detection of circulating tumor cells by nested RT-PCR may provide a feasible molecular monitoring, which might assist decision making regarding other forms of clinical surveillance.
UR - http://www.scopus.com/inward/record.url?scp=3142634626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3142634626&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2004.05.031
DO - 10.1016/j.transproceed.2004.05.031
M3 - Article
C2 - 15251328
AN - SCOPUS:3142634626
VL - 36
SP - 1344
EP - 1347
JO - Transplantation Proceedings
JF - Transplantation Proceedings
SN - 0041-1345
IS - 5
ER -